Cyplasin Biomedical Ltd., announces Licensing of Cyplasin technology

17-Feb-2009 - Canada

Cyplasin Biomedical Ltd., announced that it has completed the granting of a worldwide exclusive license to Bioxen Ltd for its Cyplasin technology for therapeutic use. Under terms of the license Bioxen will further develop the Cyplasin protein for use in skin cancer, melanoma and other potential therapeutic uses.

Financial terms were not disclosed but the license includes a financial upfront payment with an option for Bioxen to purchase the Cyplasin IP at some future date.

Cyplasin Biomedical Ltd has retained the non therapeutic rights to the technology and in the event such products are developed Cyplasin will pay a small single digit royalty to Bioxen Ltd. In the event Bioxen exercises its option to purchase the Cyplasin IP, Cyplasin will be granted an irrevocable, fully paid, world wide exclusive, license to all non therapeutic products.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...